Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States
Everest Medicines to Lead Commercialization in Greater China, Bringing Novel Innovation to Estimated 3-6 Million Chinese Patients with PSVT
Covered in this story
What has happened since
- Everest Group is up 3.2% since this was published, 51 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $EG yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Everest Group →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.